{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:32:34Z","timestamp":1770060754289,"version":"3.49.0"},"reference-count":213,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ZonMW \/ European Joint Programme on Rare Diseases (EJP RD) - JTC2022 \u201cProgerOmics\u201d"},{"name":"European Union Commission, Seventh Framework Programme"},{"name":"Innovative Medicines Initiative 2 Joint Undertaking"},{"name":"European Innovation Council \/ European Commission"},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of the Review<\/jats:title>\n                    <jats:p>Laminopathies are a diverse group of genetic disorders caused by variants in nuclear lamina proteins, with heart failure being a major cause of morbidity and mortality in patients. By shifting the perspective from distinct clinical phenotypes to a continuous spectrum of metabolic observations in laminopathies, this review aims to elucidate the molecular mechanisms underlying metabolic dysregulation in laminopathies and their impact on cardiac health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>\n                      Emerging evidence links A-type lamins to cellular metabolism, with systemic metabolic changes such as lipodystrophy, insulin resistance and hypertriglyceridemia often detected in laminopathy patients before cardiac symptoms onset. At the molecular level,\n                      <jats:italic>LMNA<\/jats:italic>\n                      variants disrupt the regulation of genes involved in fatty acid, oxidation glucose utilization, and mitochondrial function. These disturbances increase cardiomyocyte susceptibility, promoting fibrosis and apoptosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Metabolic dysregulation is a recurring observation across the laminopathy spectrum. Targeting metabolic pathways shows preclinical promise for improving cardiac outcomes in patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-025-00735-8","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:01:25Z","timestamp":1770022885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Dysregulation in Laminopathies: Implications for Heart Failure and Cardiac Health"],"prefix":"10.1007","volume":"23","author":[{"given":"T.","family":"Torfs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J. A.","family":"Veltrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lezzoche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R. B.","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A. J.","family":"Verdonschot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nabben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"735_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/mus.26782","volume":"61","author":"SA Heller","year":"2020","unstructured":"Heller SA, Shih R, Kalra R, Kang PB. Emery-Dreifuss muscular dystrophy. Muscle Nerve. 2020;61:436\u201348. https:\/\/doi.org\/10.1002\/mus.26782.","journal-title":"Muscle Nerve"},{"key":"735_CR2","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez-Cruz M, et al. Evidence of insulin resistance and other metabolic alterations in boys with Duchenne or Becker muscular dystrophy. Int J Endocrinol. 2015;2015(867273). https:\/\/doi.org\/10.1155\/2015\/867273.","DOI":"10.1155\/2015\/867273"},{"key":"735_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1210\/jc.2009-1293","volume":"95","author":"M Boschmann","year":"2010","unstructured":"Boschmann M, et al. LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance. J Clin Endocrinol Metab. 2010;95:1634\u201343. https:\/\/doi.org\/10.1210\/jc.2009-1293.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/hmg\/ddr534","volume":"21","author":"AT Bertrand","year":"2011","unstructured":"Bertrand AT, et al. DelK32-lamin A\/C has abnormal location and induces incomplete tissue maturation and severe metabolic defects leading to premature death. Hum Mol Genet. 2011;21:1037\u201348. https:\/\/doi.org\/10.1093\/hmg\/ddr534.","journal-title":"Hum Mol Genet"},{"key":"735_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/archneur.61.5.690","volume":"61","author":"E Mercuri","year":"2004","unstructured":"Mercuri E, et al. Extreme variability of phenotype in patients with an identical missense mutation in the lamin A\/C gene: from congenital onset with severe phenotype to milder classic Emery-Dreifuss variant. Arch Neurol. 2004;61:690\u20134. https:\/\/doi.org\/10.1001\/archneur.61.5.690.","journal-title":"Arch Neurol"},{"issue":"2","key":"735_CR6","first-page":"104","volume":"24","author":"V Decostre","year":"2005","unstructured":"Decostre V, Ben Yaou R, Bonne Gl. Laminopathies affecting skeletal and cardiac muscles: clinical and pathophysiological aspects. Acta Myol. 2005;24(2):104\u20139.","journal-title":"Acta Myol"},{"key":"735_CR7","doi-asserted-by":"publisher","first-page":"1142937","DOI":"10.3389\/fcell.2023.1142937","volume":"11","author":"S Cesar","year":"2023","unstructured":"Cesar S, et al. Characterization of cardiac involvement in children with LMNA-related muscular dystrophy. Front Cell Dev Biol. 2023;11:1142937. https:\/\/doi.org\/10.3389\/fcell.2023.1142937.","journal-title":"Front Cell Dev Biol"},{"key":"735_CR8","doi-asserted-by":"publisher","unstructured":"Mosbah H, et al. Looking at new unexpected disease targets in LMNA-Linked lipodystrophies in the light of complex cardiovascular phenotypes: implications for clinical practice. Cells. 2020;9. https:\/\/doi.org\/10.3390\/cells9030765.","DOI":"10.3390\/cells9030765"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"e15744","DOI":"10.1371\/journal.pone.0015744","volume":"6","author":"M Sysi-Aho","year":"2011","unstructured":"Sysi-Aho M, et al. Serum lipidomics meets cardiac magnetic resonance imaging: profiling of subjects at risk of dilated cardiomyopathy. PLoS One. 2011;6:e15744. https:\/\/doi.org\/10.1371\/journal.pone.0015744.","journal-title":"PLoS One"},{"key":"735_CR10","first-page":"309","volume":"86","author":"CM Goidescu","year":"2013","unstructured":"Goidescu CM. Dilated cardiomyopathy produced by lamin A\/C gene mutations. Clujul Med. 2013;86:309\u201312.","journal-title":"Clujul Med"},{"key":"735_CR11","doi-asserted-by":"publisher","unstructured":"Fernandez-Pombo A, et al. Clinical spectrum of LMNA-Associated type 2 Familial partial lipodystrophy: A systematic review. Cells. 2023;12. https:\/\/doi.org\/10.3390\/cells12050725.","DOI":"10.3390\/cells12050725"},{"key":"735_CR12","first-page":"33","volume":"43","author":"MG Dunnigan","year":"1974","unstructured":"Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med. 1974;43:33\u201348.","journal-title":"Q J Med"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.bbrc.2017.11.008","volume":"495","author":"M Friesen","year":"2018","unstructured":"Friesen M, Cowan CA. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism. Biochem Biophys Res Commun. 2018;495:254\u201360. https:\/\/doi.org\/10.1016\/j.bbrc.2017.11.008. https:\/\/doi.org:.","journal-title":"Biochem Biophys Res Commun"},{"key":"735_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1006\/mgme.2000.3092","volume":"71","author":"RA Hegele","year":"2000","unstructured":"Hegele RA. Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome. Mol Genet Metab. 2000;71:539\u201344. https:\/\/doi.org\/10.1006\/mgme.2000.3092.","journal-title":"Mol Genet Metab"},{"key":"735_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/01.wnl.0000255939.73424.f8","volume":"68","author":"S Spuler","year":"2007","unstructured":"Spuler S, et al. Muscle and nerve pathology in Dunnigan Familial partial lipodystrophy. Neurology. 2007;68:677\u201383. https:\/\/doi.org\/10.1212\/01.wnl.0000255939.73424.f8.","journal-title":"Neurology"},{"key":"735_CR16","doi-asserted-by":"publisher","first-page":"E1410","DOI":"10.1210\/jc.2013-1297","volume":"98","author":"H Ji","year":"2013","unstructured":"Ji H, Weatherall P, Adams-Huet B, Garg A. Increased skeletal muscle volume in women with Familial partial lipodystrophy, Dunnigan variety. J Clin Endocrinol Metab. 2013;98:E1410\u20131413. https:\/\/doi.org\/10.1210\/jc.2013-1297.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR17","doi-asserted-by":"crossref","unstructured":"Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial partial lipodystrophy (FPLD): recent insights. Diabetes Metabolic Syndrome Obes. 2020; 1531\u201344.","DOI":"10.2147\/DMSO.S206053"},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1210\/jc.2008-0123","volume":"93","author":"AK Agarwal","year":"2008","unstructured":"Agarwal AK, Kazachkova I, Ten S, Garg A. Severe mandibuloacral dysplasia-associated lipodystrophy and Progeria in a young Girl with a novel homozygous Arg527Cys LMNA mutation. J Clin Endocrinol Metab. 2008;93:4617\u201323. https:\/\/doi.org\/10.1210\/jc.2008-0123.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR19","first-page":"93","volume":"146","author":"GR Freidenberg","year":"1992","unstructured":"Freidenberg GR. Severe insulin resistance and diabetes mellitus in mandibuloacral dysplasia. Am J Dis Child. 1992;146:93\u20139.","journal-title":"Am J Dis Child"},{"key":"735_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/jcem.87.2.8258","volume":"87","author":"V Simha","year":"2002","unstructured":"Simha V, Garg A. Body fat distribution and metabolic derangements in patients with Familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab. 2002;87:776\u201385. https:\/\/doi.org\/10.1210\/jcem.87.2.8258.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR21","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1210\/clinem\/dgad606","volume":"109","author":"O Besci","year":"2023","unstructured":"Besci O, et al. Deciphering the clinical presentations in LMNA-related lipodystrophy: report of 115 cases and a systematic review. J Clin Endocrinol Metab. 2023;109:e1204\u201324. https:\/\/doi.org\/10.1210\/clinem\/dgad606.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/ajmg.a.32259","volume":"146A","author":"B Zirn","year":"2008","unstructured":"Zirn B, et al. Association of homozygous LMNA mutation R471C with new phenotype: mandibuloacral dysplasia, progeria, and rigid spine muscular dystrophy. Am J Med Genet A. 2008;146A:1049\u201354. https:\/\/doi.org\/10.1002\/ajmg.a.32259.","journal-title":"Am J Med Genet A"},{"key":"735_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2017.12.001","volume":"42","author":"V Cenni","year":"2018","unstructured":"Cenni V, et al. Mandibuloacral dysplasia: a premature ageing disease with aspects of physiological ageing. Ageing Res Rev. 2018;42:1\u201313. https:\/\/doi.org\/10.1016\/j.arr.2017.12.001.","journal-title":"Ageing Res Rev"},{"key":"735_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/chc.S59507","volume":"8","author":"L Politano","year":"2016","unstructured":"Politano L. Emerging perspectives on laminopathies. Cell Health Cytoskeleton. 2016;8:25\u201335. https:\/\/doi.org\/10.2147\/chc.S59507.","journal-title":"Cell Health Cytoskeleton"},{"key":"735_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158020","volume":"25","author":"P Kr\u00fcger","year":"2024","unstructured":"Kr\u00fcger P, Hartinger R, Djabali K. Navigating lipodystrophy: insights from laminopathies and beyond. Int J Mol Sci. 2024;25:8020.","journal-title":"Int J Mol Sci"},{"key":"735_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.5114\/aoms\/152921","volume":"18","author":"P Dobrowolski","year":"2022","unstructured":"Dobrowolski P, et al. Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish society of Hypertension, Polish society for the treatment of Obesity, Polish lipid association, Polish association for study of Liver, Polish society of family Medicine, Polish society of lifestyle Medicine, division of prevention and epidemiology Polish cardiac society, club 30 Polish cardiac society, and division of metabolic and bariatric surgery society of Polish surgeons. Arch Med Sci. 2022;18:1133\u201356. https:\/\/doi.org\/10.5114\/aoms\/152921.","journal-title":"Arch Med Sci"},{"key":"735_CR27","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1210\/jc.2007-0654","volume":"92","author":"Al Decaudain","year":"2007","unstructured":"Decaudain Al, et al. New metabolic phenotypes in Laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab. 2007;92:4835\u201344. https:\/\/doi.org\/10.1210\/jc.2007-0654.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020310","author":"C Desgrouas","year":"2020","unstructured":"Desgrouas C, et al. Unraveling LMNA mutations in metabolic syndrome: cellular phenotype and clinical pitfalls. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9020310.","journal-title":"Cells"},{"key":"735_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/pr.2018.9","volume":"83","author":"LB Gordon","year":"2018","unstructured":"Gordon LB, et al. Survey of plasma proteins in children with Progeria pre-therapy and on-therapy with Lonafarnib. Pediatr Res. 2018;83:982\u201392. https:\/\/doi.org\/10.1038\/pr.2018.9.","journal-title":"Pediatr Res"},{"key":"735_CR30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ejhg.2014.239","volume":"23","author":"F Barth\u00e9l\u00e9my","year":"2015","unstructured":"Barth\u00e9l\u00e9my F, et al. Truncated prelamin A expression in HGPS-like patients: a transcriptional study. Eur J Hum Genet. 2015;23:1051\u201361. https:\/\/doi.org\/10.1038\/ejhg.2014.239.","journal-title":"Eur J Hum Genet"},{"key":"735_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/tacg.S238715","volume":"13","author":"H Pachajoa","year":"2020","unstructured":"Pachajoa H, et al. Hutchinson-Gilford Progeria syndrome: clinical and molecular characterization. Appl Clin Genet. 2020;13:159\u201364. https:\/\/doi.org\/10.2147\/tacg.S238715.","journal-title":"Appl Clin Genet"},{"key":"735_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4274\/jcrpe.galenos.2019.2019.0126","volume":"12","author":"M Holder","year":"2020","unstructured":"Holder M, Schwitzgebel V. Early onset diabetes in two children due to Progeria, a Monogenic disease of DNA repair. J Clin Res Pediatr Endocrinol. 2020;12:315\u20138. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2019.2019.0126.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"735_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020395","author":"R Kreienkamp","year":"2020","unstructured":"Kreienkamp R, Gonzalo S. <article-title update=\"added\">Metabolic dysfunction in Hutchinson\u2013Gilford progeria syndrome. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9020395.","journal-title":"Cells"},{"key":"735_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14259","volume":"n\/a","author":"Y Hong","year":"2024","unstructured":"Hong Y, et al. <article-title update=\"added\">Cardiac and skeletal muscle manifestations in the G608G mouse model of Hutchinson\u2010Gilford progeria syndrome. Aging Cell. 2024;n\/a:e14259. https:\/\/doi.org\/10.1111\/acel.14259.","journal-title":"Aging Cell"},{"key":"735_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1750-1172-8-106","volume":"8","author":"B Donadille","year":"2013","unstructured":"Donadille B, et al. Partial lipodystrophy with severe insulin resistance and adult Progeria Werner syndrome. Orphanet J Rare Dis. 2013;8:106. https:\/\/doi.org\/10.1186\/1750-1172-8-106.","journal-title":"Orphanet J Rare Dis"},{"key":"735_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jacl.2022.06.004","volume":"16","author":"I Atallah","year":"2022","unstructured":"Atallah I, et al. Partial lipodystrophy, severe dyslipidaemia and insulin resistant diabetes as early signs of Werner syndrome. J Clin Lipidol. 2022;16:583\u201390. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.004.","journal-title":"J Clin Lipidol"},{"key":"735_CR37","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1507\/endocrj.EJ19-0014","volume":"66","author":"G He","year":"2019","unstructured":"He G, et al. Diabetes mellitus coexisted with progeria: a case report of atypical Werner syndrome with novel LMNA mutations and literature review. Endocr J. 2019;66:961\u20139. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0014.","journal-title":"Endocr J"},{"key":"735_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/ggi.14095","volume":"21","author":"K Tsukamoto","year":"2021","unstructured":"Tsukamoto K, et al. Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. Geriatr Gerontol Int. 2021;21:133\u20138. https:\/\/doi.org\/10.1111\/ggi.14095. https:\/\/doi.org:.","journal-title":"Geriatr Gerontol Int"},{"key":"735_CR39","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.18632\/aging.101265","volume":"9","author":"M Yamaga","year":"2017","unstructured":"Yamaga M, et al. Werner syndrome: a model for sarcopenia due to accelerated aging. Aging. 2017;9:1738\u201344. https:\/\/doi.org\/10.18632\/aging.101265.","journal-title":"Aging"},{"key":"735_CR40","doi-asserted-by":"publisher","unstructured":"Yanhua X, Suxian Z. Cerebral haemorrhage in a young patient with atypical Werner syndrome due to mutations in LMNA. Front Endocrinol. 2018;9. https:\/\/doi.org\/10.3389\/fendo.2018.00433.","DOI":"10.3389\/fendo.2018.00433"},{"key":"735_CR41","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1002\/ajmg.a.34336","volume":"155a","author":"FM Hisama","year":"2011","unstructured":"Hisama FM, et al. Coronary artery disease in a Werner syndrome-like form of Progeria characterized by low levels of progerin, a splice variant of lamin A. Am J Med Genet A. 2011;155a:3002\u20136. https:\/\/doi.org\/10.1002\/ajmg.a.34336.","journal-title":"Am J Med Genet A"},{"key":"735_CR42","unstructured":"Gondim F, FP T. Charcot-Marie-Tooth disease: CMT2, CMT4 and others. Medlink Neurology. 4th ed.(Internet Address). San Diego: MedLink Corporation (last update: 11\/12 (2013)."},{"key":"735_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5734\/JGM.2021.18.2.83","volume":"18","author":"HM Kwon","year":"2021","unstructured":"Kwon HM, Choi B-O. Analyzing clinical and genetic aspects of axonal Charcot\u2013Marie-Tooth disease. J Genet Med. 2021;18:83\u201393. https:\/\/doi.org\/10.5734\/JGM.2021.18.2.83.","journal-title":"J Genet Med"},{"key":"735_CR44","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archinte.1979.03630470069021","volume":"139","author":"JM Isner","year":"1979","unstructured":"Isner JM, Hawley RJ, Weintraub AM, Engel WK. Cardiac findings in Charcot-Marie-Tooth disease. A prospective study of 68 patients. Arch Intern Med. 1979;139:1161\u20135.","journal-title":"Arch Intern Med"},{"key":"735_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.apcsb.2024.06.002","volume":"143","author":"R Chauhan","year":"2025","unstructured":"Chauhan R, et al. Role of lamins in cellular physiology and cancer. Adv Protein Chem Struct Biol. 2025;143:119\u201353. https:\/\/doi.org\/10.1016\/bs.apcsb.2024.06.002.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"735_CR46","doi-asserted-by":"publisher","unstructured":"Peng Y, Tang Q, Xiao F, Fu N. Regulation of lipid metabolism by lamin in Mutation-Related diseases. Front Pharmacol. 2022;13\u20132022. https:\/\/doi.org\/10.3389\/fphar.2022.820857.","DOI":"10.3389\/fphar.2022.820857"},{"key":"735_CR47","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jcmg.2025.01.004","volume":"18","author":"C-C Topriceanu","year":"2025","unstructured":"Topriceanu C-C, et al. The cardiovascular magnetic resonance phenotype of lamin heart disease. JACC: Cardiovasc Imaging. 2025;18:644\u201360. https:\/\/doi.org\/10.1016\/j.jcmg.2025.01.004. https:\/\/doi.org:.","journal-title":"JACC: Cardiovasc Imaging"},{"key":"735_CR48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/19491034.2018.1489195","volume":"9","author":"G Peretto","year":"2018","unstructured":"Peretto G, et al. Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease. Nucleus. 2018;9:380\u201391. https:\/\/doi.org\/10.1080\/19491034.2018.1489195.","journal-title":"Nucleus"},{"key":"735_CR49","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.2337\/db18-0449","volume":"67","author":"T Jelenik","year":"2018","unstructured":"Jelenik T, et al. Insulin resistance and vulnerability to cardiac ischemia. Diabetes. 2018;67:2695\u2013702. https:\/\/doi.org\/10.2337\/db18-0449.","journal-title":"Diabetes"},{"key":"735_CR50","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1096\/fj.14-253971","volume":"28","author":"C Vernochet","year":"2014","unstructured":"Vernochet C, et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. FASEB J. 2014;28:4408\u201319. https:\/\/doi.org\/10.1096\/fj.14-253971.","journal-title":"FASEB J"},{"key":"735_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3920195","volume":"2017","author":"L Schirone","year":"2017","unstructured":"Schirone L. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev. 2017;2017:3920195. https:\/\/doi.org\/10.1155\/2017\/3920195.","journal-title":"Oxid Med Cell Longev"},{"key":"735_CR52","doi-asserted-by":"publisher","unstructured":"Bhide S, Chandran S, Rajasekaran NS, Melkani GC. Genetic and pathophysiological basis of cardiac and skeletal muscle laminopathies. Genes (Basel). 2024;15. https:\/\/doi.org\/10.3390\/genes15081095.","DOI":"10.3390\/genes15081095"},{"key":"735_CR53","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1152\/physrev.00047.2005","volume":"86","author":"JLV Broers","year":"2006","unstructured":"Broers JLV, Ramaekers FCS, Bonne G, Yaou RB, Hutchison CJ. Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev. 2006;86:967\u20131008. https:\/\/doi.org\/10.1152\/physrev.00047.2005.","journal-title":"Physiol Rev"},{"key":"735_CR54","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.yexcr.2007.03.028","volume":"313","author":"HJ Worman","year":"2007","unstructured":"Worman HJ, Bonne G. Laminopathies: a wide spectrum of human diseases. Exp Cell Res. 2007;313:2121\u201333. https:\/\/doi.org\/10.1016\/j.yexcr.2007.03.028.","journal-title":"Exp Cell Res"},{"key":"735_CR55","doi-asserted-by":"publisher","unstructured":"4th International Meeting on Laminopathies, Madrid, 9\u201312, May. 2023. J Neuromusc Dis. 2023; 10, S1-S54. https:\/\/doi.org\/10.3233\/JND-239001","DOI":"10.3233\/JND-239001"},{"key":"735_CR56","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1073\/pnas.1810070116","volume":"116","author":"B Nmezi","year":"2019","unstructured":"Nmezi B, et al. Concentric organization of A-and B-type lamins predicts their distinct roles in the spatial organization and stability of the nuclear lamina. Proc Natl Acad Sci U S A. 2019;116:4307\u201315.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"735_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrm3488","volume":"14","author":"B Burke","year":"2013","unstructured":"Burke B, Stewart CL. The nuclear lamins: flexibility in function. Nat Rev Mol Cell Biol. 2013;14:13\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"735_CR58","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0282","author":"G Treiber","year":"2021","unstructured":"Treiber G. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. Eur J Endocrinol. 2021. https:\/\/doi.org\/10.1530\/EJE-21-0282.","journal-title":"Eur J Endocrinol"},{"key":"735_CR59","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/cells9030765","volume":"9","author":"H Mosbah","year":"2020","unstructured":"Mosbah H, et al. Looking at new unexpected disease targets in LMNA-linked lipodystrophies in the light of complex cardiovascular phenotypes: implications for clinical practice. Cells. 2020;9:765.","journal-title":"Cells"},{"key":"735_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/eje-21-0282","volume":"185","author":"G Treiber","year":"2021","unstructured":"Treiber G, et al. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies. Eur J Endocrinol. 2021;185:453\u201362. https:\/\/doi.org\/10.1530\/eje-21-0282.","journal-title":"Eur J Endocrinol"},{"key":"735_CR61","doi-asserted-by":"publisher","first-page":"25870","DOI":"10.1073\/pnas.1917225116","volume":"116","author":"NY Chen","year":"2019","unstructured":"Chen NY, et al. An absence of lamin B1 in migrating neurons causes nuclear membrane ruptures and cell death. Proc Natl Acad Sci U S A. 2019;116:25870\u20139. https:\/\/doi.org\/10.1073\/pnas.1917225116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"735_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2023.102257","volume":"85","author":"Y Kim","year":"2023","unstructured":"Kim Y. The impact of altered lamin B1 levels on nuclear lamina structure and function in aging and human diseases. Curr Opin Cell Biol. 2023;85:102257. https:\/\/doi.org\/10.1016\/j.ceb.2023.102257.","journal-title":"Curr Opin Cell Biol"},{"key":"735_CR63","doi-asserted-by":"publisher","first-page":"e139131","DOI":"10.1016\/j.repce.2014.08.009","volume":"34","author":"N Cabanelas","year":"2015","unstructured":"Cabanelas N, Martins V. Laminopathies: a pandora\u2019s box of heart failure, bradyarrhythmias and sudden death. Revista Portuguesa De Cardiologia (English Edition). 2015;34:e139131-5. https:\/\/doi.org\/10.1016\/j.repce.2014.08.009.","journal-title":"Revista Portuguesa De Cardiologia (English Edition)"},{"key":"735_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13023-019-1245-8","volume":"14","author":"R Ditaranto","year":"2019","unstructured":"Ditaranto R, et al. Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. Orphanet J Rare Dis. 2019;14:263. https:\/\/doi.org\/10.1186\/s13023-019-1245-8.","journal-title":"Orphanet J Rare Dis"},{"key":"735_CR65","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1093\/hmg\/ddr294","volume":"20","author":"A Dutour","year":"2011","unstructured":"Dutour A, et al. High prevalence of laminopathies among patients with metabolic syndrome. Hum Mol Genet. 2011;20:3779\u201386. https:\/\/doi.org\/10.1093\/hmg\/ddr294.","journal-title":"Hum Mol Genet"},{"key":"735_CR66","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11886-016-0755-4","volume":"18","author":"AE Brown","year":"2016","unstructured":"Brown AE, Walker M. Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep. 2016;18:75. https:\/\/doi.org\/10.1007\/s11886-016-0755-4.","journal-title":"Curr Cardiol Rep"},{"key":"735_CR67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cbpa.2006.09.014","volume":"146","author":"IF Kodde","year":"2007","unstructured":"Kodde IF, van der Stok J, Smolenski RT, de Jong JW. Metabolic and genetic regulation of cardiac energy substrate preference. Comp Biochem Physiol A: Mol Integr Physiol. 2007;146:26\u201339. https:\/\/doi.org\/10.1016\/j.cbpa.2006.09.014.","journal-title":"Comp Biochem Physiol A: Mol Integr Physiol"},{"issue":"Suppl 1","key":"735_CR68","first-page":"S3","volume":"12","author":"WC Stanley","year":"2001","unstructured":"Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron Artery Dis. 2001;12(Suppl 1):S3\u20137.","journal-title":"Coron Artery Dis"},{"key":"735_CR69","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.biochi.2015.10.013","volume":"124","author":"TM Griffin","year":"2016","unstructured":"Griffin TM, Humphries KM, Kinter M, Lim H-Y, Szweda L. I. Nutrient sensing and utilization: getting to the heart of metabolic flexibility. Biochimie. 2016;124:74\u201383. https:\/\/doi.org\/10.1016\/j.biochi.2015.10.013. https:\/\/doi.org:.","journal-title":"Biochimie"},{"key":"735_CR70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/j.2040-4603.2016.tb00680.x","volume":"6","author":"D Shao","year":"2016","unstructured":"Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol. 2016;6:331\u201351. https:\/\/doi.org\/10.1002\/j.2040-4603.2016.tb00680.x.","journal-title":"Compr Physiol"},{"key":"735_CR71","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41569-018-0115-8","volume":"15","author":"M Nabben","year":"2018","unstructured":"Nabben M, Luiken JJ, Glatz JF. Metabolic remodelling in heart failure revisited. Nat Rev Cardiol. 2018;15:780\u2013780.","journal-title":"Nat Rev Cardiol"},{"key":"735_CR72","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1172\/JCI113822","volume":"82","author":"E Gertz","year":"1988","unstructured":"Gertz E, Wisneski J, Stanley W, Neese R. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Invest. 1988;82:2017\u201325.","journal-title":"J Clin Invest"},{"key":"735_CR73","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1258\/ebm.2012.012025","volume":"237","author":"KJ Drake","year":"2012","unstructured":"Drake KJ, Sidorov VY, McGuinness OP, Wasserman DH, Wikswo JP. Amino acids as metabolic substrates during cardiac ischemia. Exp Biol Med. 2012;237:1369\u201378.","journal-title":"Exp Biol Med"},{"key":"735_CR74","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/cvr\/cvaa143","volume":"117","author":"KL Ho","year":"2021","unstructured":"Ho KL, et al. Ketones can become the major fuel source for the heart but do not increase cardiac efficiency. Cardiovasc Res. 2021;117:1178\u201387.","journal-title":"Cardiovasc Res"},{"key":"735_CR75","doi-asserted-by":"publisher","unstructured":"Curovic I. The role of resistance exercise-induced local metabolic stress in mediating systemic health and functional adaptations: could condensed training volume unlock greater benefits beyond time efficiency? Front Physiol. 2025;16\u20132025. https:\/\/doi.org\/10.3389\/fphys.2025.1549609.","DOI":"10.3389\/fphys.2025.1549609"},{"key":"735_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5662\/wjm.v7.i2.46","volume":"7","author":"MC de Freitas","year":"2017","unstructured":"de Freitas MC, Gerosa-Neto J, Zanchi NE, Lira FS, Rossi FE. Role of metabolic stress for enhancing muscle adaptations: practical applications. World Journal of Methodology. 2017;7:46\u201354. https:\/\/doi.org\/10.5662\/wjm.v7.i2.46.","journal-title":"World Journal of Methodology"},{"key":"735_CR77","doi-asserted-by":"publisher","first-page":"831829","DOI":"10.3389\/fphys.2022.831829","volume":"13","author":"X Shi","year":"2022","unstructured":"Shi X, Qiu H. New insights into energy substrate utilization and metabolic remodeling in cardiac physiological adaption. Front Physiol. 2022;13:831829. https:\/\/doi.org\/10.3389\/fphys.2022.831829.","journal-title":"Front Physiol"},{"key":"735_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/6799","volume":"21","author":"G Bonne","year":"1999","unstructured":"Bonne G, et al. Mutations in the gene encoding lamin A\/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 1999;21:285\u20138. https:\/\/doi.org\/10.1038\/6799.","journal-title":"Nat Genet"},{"key":"735_CR79","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12964-024-01546-5","volume":"22","author":"RJA Veltrop","year":"2024","unstructured":"Veltrop RJA, et al. From gene to mechanics: a comprehensive insight into the mechanobiology of LMNA mutations in cardiomyopathy. Cell Commun Signal. 2024;22:197. https:\/\/doi.org\/10.1186\/s12964-024-01546-5.","journal-title":"Cell Commun Signal"},{"key":"735_CR80","doi-asserted-by":"publisher","unstructured":"Wu XY, et al. The pathogenic mechanisms of and novel therapies for lamin A\/C-Related dilated cardiomyopathy based on Patient-Specific pluripotent stem cell platforms and animal models. Pharmaceuticals (Basel). 2024;17. https:\/\/doi.org\/10.3390\/ph17081030.","DOI":"10.3390\/ph17081030"},{"key":"735_CR81","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cells13171479","volume":"13","author":"MV Zaragoza","year":"2024","unstructured":"Zaragoza MV, et al. LMNA-related dilated cardiomyopathy: single-cell transcriptomics during patient-derived iPSC differentiation support cell type and lineage-specific dysregulation of gene expression and development for cardiomyocytes and epicardium-derived cells with lamin A\/C haploinsufficiency. Cells. 2024;13:1479.","journal-title":"Cells"},{"key":"735_CR82","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jacbts.2024.05.011","volume":"9","author":"Z Du","year":"2024","unstructured":"Du Z, et al. SIRT1 ameliorates lamin A\/C deficiency-induced cardiac dysfunction by promoting mitochondrial bioenergetics. JACC: Basic to Translational Science. 2024;9:1211\u201330. https:\/\/doi.org\/10.1016\/j.jacbts.2024.05.011.","journal-title":"JACC: Basic to Translational Science"},{"key":"735_CR83","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/19491034.2018.1456217","volume":"9","author":"C Vigouroux","year":"2018","unstructured":"Vigouroux C, et al. Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus. 2018;9:251\u201364. https:\/\/doi.org\/10.1080\/19491034.2018.1456217.","journal-title":"Nucleus"},{"key":"735_CR84","doi-asserted-by":"publisher","first-page":"23842","DOI":"10.1038\/s41598-025-08495-0","volume":"15","author":"LY Wong","year":"2025","unstructured":"Wong LY, et al. Clinical and metabolic consequences of a historic pathogenic lamin A\/C founder variant. Sci Rep. 2025;15:23842. https:\/\/doi.org\/10.1038\/s41598-025-08495-0.","journal-title":"Sci Rep"},{"key":"735_CR85","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","volume":"5","author":"QG Karwi","year":"2018","unstructured":"Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5:68. https:\/\/doi.org\/10.3389\/fcvm.2018.00068.","journal-title":"Front Cardiovasc Med"},{"key":"735_CR86","doi-asserted-by":"publisher","unstructured":"Zuela-Sopilniak, N. et al. Nuclear envelope rupture in cardiomyocytes orchestrates early transcriptomic changes and immune activation in LMNA-DCM that are reversed by LINC complex disruption. bioRxiv, 2024.2006.2011.598511 (2025). https:\/\/doi.org\/10.1101\/2024.06.11.598511","DOI":"10.1101\/2024.06.11.598511"},{"key":"735_CR87","doi-asserted-by":"publisher","DOI":"10.20517\/jca.2022.26","author":"X Wang","year":"2022","unstructured":"Wang X, Luo W, Chang J. Deficient Lmna in fibroblasts: an emerging role of non-cardiomyocytes in DCM. J Cardiovasc Aging. 2022. https:\/\/doi.org\/10.20517\/jca.2022.26.","journal-title":"J Cardiovasc Aging"},{"key":"735_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.44.suppl_1.3105","volume":"44","author":"D Wu","year":"2024","unstructured":"Wu D, et al. Abstract 3105: lamin mutations: single nuclei multiomic analysis reveals endothelial cell dysfunction and its cardiovascular implications. Arterioscler Thromb Vasc Biol. 2024;44:A3105-A3105. https:\/\/doi.org\/10.1161\/atvb.44.suppl_1.3105.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"735_CR89","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1016\/j.febslet.2009.10.054","volume":"583","author":"J Nielsen","year":"2009","unstructured":"Nielsen J. Systems biology of lipid metabolism: from yeast to human. FEBS Lett. 2009;583:3905\u201313. https:\/\/doi.org\/10.1016\/j.febslet.2009.10.054. https:\/\/doi.org:.","journal-title":"FEBS Lett"},{"key":"735_CR90","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5507\/bp.2017.002","volume":"161","author":"A Smekal","year":"2017","unstructured":"Smekal A, Vaclavik J. Adipokines and cardiovascular disease: a comprehensive review. Biomed Pap. 2017;161:31\u201340. https:\/\/doi.org\/10.5507\/bp.2017.002.","journal-title":"Biomed Pap"},{"key":"735_CR91","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.biochi.2012.06.030","volume":"94","author":"MT Villarreal-Molina","year":"2012","unstructured":"Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie. 2012;94:2143\u20139. https:\/\/doi.org\/10.1016\/j.biochi.2012.06.030.","journal-title":"Biochimie"},{"key":"735_CR92","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/cen.14426","volume":"94","author":"AJ Eldin","year":"2021","unstructured":"Eldin AJ, et al. Cardiac phenotype in familial partial lipodystrophy. Clin Endocrinol (Oxf). 2021;94:1043\u201353. https:\/\/doi.org\/10.1111\/cen.14426.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"735_CR93","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1210\/jc.2002-021575","volume":"88","author":"V Simha","year":"2003","unstructured":"Simha V, Agarwal AK, Oral EA, Fryns J-P, Garg A. Genetic and phenotypic heterogeneity in patients with mandibuloacral Dysplasia-Associated lipodystrophy. J Clin Endocrinol Metab. 2003;88:2821\u20134. https:\/\/doi.org\/10.1210\/jc.2002-021575.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR94","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/hmg\/ddac264","volume":"32","author":"JI de Las Heras","year":"2023","unstructured":"de Las Heras JI, et al. Metabolic, fibrotic and splicing pathways are all altered in Emery-Dreifuss muscular dystrophy spectrum patients to differing degrees. Hum Mol Genet. 2023;32:1010\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddac264.","journal-title":"Hum Mol Genet"},{"key":"735_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102248","author":"D Cardoso","year":"2020","unstructured":"Cardoso D, Muchir A. Need for NAD+: focus on striated muscle laminopathies. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9102248.","journal-title":"Cells"},{"key":"735_CR96","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s42255-021-00440-5","volume":"3","author":"G Bidault","year":"2021","unstructured":"Bidault G, et al. SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation. Nat Metab. 2021;3:1150\u201362. https:\/\/doi.org\/10.1038\/s42255-021-00440-5.","journal-title":"Nat Metab"},{"key":"735_CR97","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1194\/jlr.M700533-JLR200","volume":"49","author":"F Diraison","year":"2008","unstructured":"Diraison F, et al. SREBP1 is required for the induction by glucose of pancreatic \u03b2-cell genes involved in glucose sensing\u2009<\u2009sup\u2009>\u2009s\u20de. J Lipid Res. 2008;49:814\u201322. https:\/\/doi.org\/10.1194\/jlr.M700533-JLR200.","journal-title":"J Lipid Res"},{"key":"735_CR98","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/hmg\/ddi158","volume":"14","author":"C Capanni","year":"2005","unstructured":"Capanni C, et al. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet. 2005;14:1489\u2013502. https:\/\/doi.org\/10.1093\/hmg\/ddi158.","journal-title":"Hum Mol Genet"},{"key":"735_CR99","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","volume":"50","author":"M Caron","year":"2001","unstructured":"Caron M, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378\u201388.","journal-title":"Diabetes"},{"key":"735_CR100","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/47254","volume":"402","author":"I Barroso","year":"1999","unstructured":"Barroso I, et al. Dominant negative mutations in human PPAR\u03b3 associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880\u20133.","journal-title":"Nature"},{"key":"735_CR101","doi-asserted-by":"publisher","first-page":"1114459","DOI":"10.3389\/fcvm.2023.1114459","volume":"10","author":"KR Gaar-Humphreys","year":"2023","unstructured":"Gaar-Humphreys KR, et al. Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies. Front Cardiovasc Med. 2023;10:1114459. https:\/\/doi.org\/10.3389\/fcvm.2023.1114459.","journal-title":"Front Cardiovasc Med"},{"key":"735_CR102","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18:809\u201323. https:\/\/doi.org\/10.1038\/s41569-021-00569-6.","journal-title":"Nat Rev Cardiol"},{"key":"735_CR103","doi-asserted-by":"publisher","first-page":"e31812","DOI":"10.1371\/journal.pone.0031812","volume":"7","author":"B Knebel","year":"2012","unstructured":"Knebel B, et al. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS One. 2012;7:e31812. https:\/\/doi.org\/10.1371\/journal.pone.0031812.","journal-title":"PLoS One"},{"key":"735_CR104","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150295","volume":"36","author":"A Nsiah-Sefaa","year":"2016","unstructured":"Nsiah-Sefaa A, McKenzie M. Combined defects in oxidative phosphorylation and fatty acid \u03b2-oxidation in mitochondrial disease. Biosci Rep. 2016;36:e00313. https:\/\/doi.org\/10.1042\/BSR20150295.","journal-title":"Biosci Rep"},{"key":"735_CR105","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","volume":"1863","author":"JS Bhatti","year":"2017","unstructured":"Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders - a step towards mitochondria based therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2017;1863:1066\u201377. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.010.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"735_CR106","doi-asserted-by":"publisher","unstructured":"Peng Y, Tang Q, Xiao F, Fu N. Regulation of lipid metabolism by lamin in Mutation-Related diseases. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.820857.","DOI":"10.3389\/fphar.2022.820857"},{"key":"735_CR107","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1540-8167.2007.01017.x","volume":"19","author":"E Hookana","year":"2008","unstructured":"Hookana E, et al. Cardiac arrest and left ventricular fibrosis in a Finnish family with the lamin A\/C mutation. J Cardiovasc Electrophysiol. 2008;19:743\u20137. https:\/\/doi.org\/10.1111\/j.1540-8167.2007.01017.x.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"735_CR108","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.hrcr.2018.11.009","volume":"5","author":"A Bhaskaran","year":"2019","unstructured":"Bhaskaran A, et al. Biventricular, endocardial, and epicardial substrate characterization for ventricular tachycardia and correlation with whole-heart macropathology and histopathology in a patient with lamin A\/C cardiomyopathy. HeartRhythm Case Rep. 2019;5:128\u201333. https:\/\/doi.org\/10.1016\/j.hrcr.2018.11.009.","journal-title":"HeartRhythm Case Rep"},{"key":"735_CR109","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12933-024-02517-3","volume":"23","author":"Y Xu","year":"2024","unstructured":"Xu Y, et al. Increased epicardial adipose tissue is associated with left ventricular reverse remodeling in dilated cardiomyopathy. Cardiovasc Diabetol. 2024;23:447. https:\/\/doi.org\/10.1186\/s12933-024-02517-3.","journal-title":"Cardiovasc Diabetol"},{"key":"735_CR110","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jacasi.2023.06.001","volume":"3","author":"S Saha","year":"2023","unstructured":"Saha S, et al. A comprehensive insight and mechanistic understanding of the lipidomic alterations associated with DCM. JACC Asia. 2023;3:539\u201355. https:\/\/doi.org\/10.1016\/j.jacasi.2023.06.001.","journal-title":"JACC Asia"},{"key":"735_CR111","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1101\/gad.1992411","volume":"25","author":"HY Lim","year":"2011","unstructured":"Lim HY, Wang W, Wessells RJ, Ocorr K, Bodmer R. Phospholipid homeostasis regulates lipid metabolism and cardiac function through SREBP signaling in drosophila. Genes Dev. 2011;25:189\u2013200. https:\/\/doi.org\/10.1101\/gad.1992411.","journal-title":"Genes Dev"},{"key":"735_CR112","doi-asserted-by":"crossref","unstructured":"Rodriguez-Gonzalez M, Perez-Reviriego AA, Castellano-Martinez A, Cascales-Poyatos H. M. Cardiac complications in patients with propionic acidemia. J Rare Dis Res Treat 3 (2018).","DOI":"10.29245\/2572-9411\/2018\/3.1162"},{"key":"735_CR113","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","volume":"118","author":"PC Schulze","year":"2016","unstructured":"Schulze PC, Drosatos K, Goldberg IJ. Lipid use and misuse by the heart. Circ Res. 2016;118:1736\u201351. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306842.","journal-title":"Circ Res"},{"key":"735_CR114","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/hmg\/ddt172","volume":"22","author":"ME Cattin","year":"2013","unstructured":"Cattin ME, et al. Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity. Hum Mol Genet. 2013;22:3152\u201364. https:\/\/doi.org\/10.1093\/hmg\/ddt172.","journal-title":"Hum Mol Genet"},{"key":"735_CR115","doi-asserted-by":"publisher","first-page":"820857","DOI":"10.3389\/fphar.2022.820857","volume":"13","author":"Y Peng","year":"2022","unstructured":"Peng Y, Tang Q, Xiao F, Fu N. Regulation of lipid metabolism by lamin in mutation-related diseases. Front Pharmacol. 2022;13:820857. https:\/\/doi.org\/10.3389\/fphar.2022.820857.","journal-title":"Front Pharmacol"},{"key":"735_CR116","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1161\/01.ATV.0000136384.53705.c9","volume":"24","author":"NI Steinle","year":"2004","unstructured":"Steinle NI, et al. Variation in the Lamin A\/C gene. Arterioscler Thromb Vasc Biol. 2004;24:1708\u201313. https:\/\/doi.org\/10.1161\/01.ATV.0000136384.53705.c9.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"735_CR117","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1210\/clinem\/dgab725","volume":"107","author":"V Simha","year":"2022","unstructured":"Simha V, et al. Impaired muscle mitochondrial function in familial partial lipodystrophy. J Clin Endocrinol Metab. 2022;107:346\u201362. https:\/\/doi.org\/10.1210\/clinem\/dgab725.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR118","doi-asserted-by":"publisher","unstructured":"Meinke P, Hintze S, Limmer S, Schoser B. Myotonic Dystrophy\u2014A Progeroid Disease? Frontiers in Neurology Volume 9\u20132018 (2018). https:\/\/doi.org\/10.3389\/fneur.2018.00601","DOI":"10.3389\/fneur.2018.00601"},{"key":"735_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/biology9100338","author":"C \u00d6stlund","year":"2020","unstructured":"\u00d6stlund C, Hernandez-Ono A, Shin JY. The nuclear envelope in lipid metabolism and pathogenesis of NAFLD. Biology. 2020. https:\/\/doi.org\/10.3390\/biology9100338.","journal-title":"Biology"},{"key":"735_CR120","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.bbalip.2009.09.023","volume":"1801","author":"AR Wende","year":"2010","unstructured":"Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311\u20139. https:\/\/doi.org\/10.1016\/j.bbalip.2009.09.023.","journal-title":"Biochim Biophys Acta"},{"key":"735_CR121","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/19491034.2018.1456217","volume":"9","author":"C Vigouroux","year":"2018","unstructured":"Vigouroux C, et al. Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus. 2018;9:235\u201348. https:\/\/doi.org\/10.1080\/19491034.2018.1456217.","journal-title":"Nucleus"},{"key":"735_CR122","doi-asserted-by":"publisher","first-page":"E130","DOI":"10.1152\/ajpendo.00158.2021","volume":"321","author":"ED Abel","year":"2021","unstructured":"Abel ED. Insulin signaling in the heart. Am J Physiol Endocrinol Metab. 2021;321:E130\u201345. https:\/\/doi.org\/10.1152\/ajpendo.00158.2021.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"735_CR123","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1161\/atvbaha.111.241984","volume":"32","author":"ED Abel","year":"2012","unstructured":"Abel ED, O\u2019Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32:2068\u201376. https:\/\/doi.org\/10.1161\/atvbaha.111.241984.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"735_CR124","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/489187","volume":"2013","author":"P Patel","year":"2013","unstructured":"Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes. 2013;2013:489187. https:\/\/doi.org\/10.1155\/2013\/489187.","journal-title":"J Obes"},{"key":"735_CR125","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3390\/nu5062019","volume":"5","author":"P Patel","year":"2013","unstructured":"Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients. 2013;5:2019\u201327. https:\/\/doi.org\/10.3390\/nu5062019.","journal-title":"Nutrients"},{"key":"735_CR126","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","volume":"417","author":"A Yadav","year":"2013","unstructured":"Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta. 2013;417:80\u20134. https:\/\/doi.org\/10.1016\/j.cca.2012.12.007.","journal-title":"Clin Chim Acta"},{"key":"735_CR127","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11306-019-1558-6","volume":"15","author":"G Monnerat","year":"2019","unstructured":"Monnerat G, et al. Metabolomic profiling suggests systemic signatures of premature aging induced by Hutchinson\u2013Gilford Progeria syndrome. Metabolomics. 2019;15:100. https:\/\/doi.org\/10.1007\/s11306-019-1558-6.","journal-title":"Metabolomics"},{"key":"735_CR128","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1210\/jc.2003-031658","volume":"89","author":"MC Vantyghem","year":"2004","unstructured":"Vantyghem MC, et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab. 2004;89:5337\u201346. https:\/\/doi.org\/10.1210\/jc.2003-031658.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR129","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/hmg\/ddac264","volume":"32","author":"JI de las Heras","year":"2022","unstructured":"de las Heras JI, et al. Metabolic, fibrotic and splicing pathways are all altered in Emery-Dreifuss muscular dystrophy spectrum patients to differing degrees. Hum Mol Genet. 2022;32:1010\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddac264.","journal-title":"Hum Mol Genet"},{"key":"735_CR130","doi-asserted-by":"publisher","first-page":"e13203","DOI":"10.1111\/acel.13203","volume":"19","author":"V Fanjul","year":"2020","unstructured":"Fanjul V, et al. Identification of common cardiometabolic alterations and deregulated pathways in mouse and pig models of aging. Aging Cell. 2020;19:e13203. https:\/\/doi.org\/10.1111\/acel.13203.","journal-title":"Aging Cell"},{"key":"735_CR131","doi-asserted-by":"publisher","first-page":"106ra107","DOI":"10.1126\/scitranslmed.3002847","volume":"3","author":"FG Osorio","year":"2011","unstructured":"Osorio FG. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med. 2011;3:106ra107-106ra107. https:\/\/doi.org\/10.1126\/scitranslmed.3002847.","journal-title":"Sci Transl Med"},{"key":"735_CR132","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jcmgh.2017.06.005","volume":"4","author":"R Kwan","year":"2017","unstructured":"Kwan R, et al. Hepatocyte-specific deletion of mouse lamin A\/C leads to male-selective steatohepatitis. Cell Mol Gastroenterol Hepatol. 2017;4:365\u201383. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.06.005.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"735_CR133","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1463-1326.2007.00779.x","volume":"9","author":"H Shimano","year":"2007","unstructured":"Shimano H, et al. Sterol regulatory element-binding protein-1c and pancreatic beta-cell dysfunction. Diabetes Obes Metab. 2007;9(2):133\u20139. https:\/\/doi.org\/10.1111\/j.1463-1326.2007.00779.x.","journal-title":"Diabetes Obes Metab"},{"key":"735_CR134","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2337\/db19-0377","volume":"69","author":"M de Toledo","year":"2020","unstructured":"de Toledo M, et al. Lamin C counteracts glucose intolerance in aging, obesity, and diabetes through \u03b2-cell adaptation. Diabetes. 2020;69:647\u201360. https:\/\/doi.org\/10.2337\/db19-0377.","journal-title":"Diabetes"},{"key":"735_CR135","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4239\/wjd.v5.i2.146","volume":"5","author":"AE Bunner","year":"2014","unstructured":"Bunner AE, Chandrasekera PC, Barnard ND. Knockout mouse models of insulin signaling: relevance past and future. World J Diabetes. 2014;5:146\u201359. https:\/\/doi.org\/10.4239\/wjd.v5.i2.146.","journal-title":"World J Diabetes"},{"key":"735_CR136","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1038\/sj.embor.7400422","volume":"6","author":"L Demetrius","year":"2005","unstructured":"Demetrius L. Of mice and men: when it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep. 2005;6:S39\u201344. https:\/\/doi.org\/10.1038\/sj.embor.7400422.","journal-title":"EMBO Rep"},{"key":"735_CR137","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.yexcr.2007.03.026","volume":"313","author":"CL Stewart","year":"2007","unstructured":"Stewart CL, Kozlov S, Fong LG, Young SG. Mouse models of the laminopathies. Exp Cell Res. 2007;313:2144\u201356. https:\/\/doi.org\/10.1016\/j.yexcr.2007.03.026.","journal-title":"Exp Cell Res"},{"key":"735_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165579","volume":"1866","author":"JFC Glatz","year":"2020","unstructured":"Glatz JFC, et al. Re-balancing cellular energy substrate metabolism to mend the failing heart. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020;1866:165579. https:\/\/doi.org\/10.1016\/j.bbadis.2019.165579.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"735_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413384","author":"P Kowalczyk","year":"2021","unstructured":"Kowalczyk P. Mitochondrial oxidative stress\u2014a causative factor and therapeutic target in many diseases. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222413384.","journal-title":"Int J Mol Sci"},{"key":"735_CR140","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1242\/jcs.139394","volume":"127","author":"C Pennanen","year":"2014","unstructured":"Pennanen C, et al. Mitochondrial fission is required for cardiomyocyte hypertrophy mediated by a Ca2+-calcineurin signaling pathway. J Cell Sci. 2014;127:2659\u201371. https:\/\/doi.org\/10.1242\/jcs.139394.","journal-title":"J Cell Sci"},{"key":"735_CR141","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00424-020-02506-x","volume":"473","author":"LA Blatter","year":"2021","unstructured":"Blatter LA, Kanaporis G, Martinez-Hernandez E, Oropeza-Almazan Y, Banach K. Excitation-contraction coupling and calcium release in atrial muscle. Pflugers Arch. 2021;473:317\u201329. https:\/\/doi.org\/10.1007\/s00424-020-02506-x.","journal-title":"Pflugers Arch"},{"key":"735_CR142","doi-asserted-by":"publisher","first-page":"9948","DOI":"10.1093\/nar\/gkac741","volume":"50","author":"S Maynard","year":"2022","unstructured":"Maynard S, et al. Lamin A\/C impairments cause mitochondrial dysfunction by attenuating PGC1\u03b1 and the NAMPT-NAD\u2009+\u2009pathway. Nucleic Acids Res. 2022;50:9948\u201365. https:\/\/doi.org\/10.1093\/nar\/gkac741.","journal-title":"Nucleic Acids Res"},{"key":"735_CR143","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jns.2008.03.017","volume":"271","author":"A Fidzia\u0144ska","year":"2008","unstructured":"Fidzia\u0144ska A, et al. Obliteration of cardiomyocyte nuclear architecture in a patient with LMNA gene mutation. J Neurol Sci. 2008;271:91\u20136. https:\/\/doi.org\/10.1016\/j.jns.2008.03.017.","journal-title":"J Neurol Sci"},{"key":"735_CR144","doi-asserted-by":"publisher","first-page":"e15167","DOI":"10.1371\/journal.pone.0015167","volume":"5","author":"D Lu","year":"2010","unstructured":"Lu D, et al. LMNA E82K mutation activates FAS and mitochondrial pathways of apoptosis in heart tissue specific transgenic mice. PLoS One. 2010;5:e15167. https:\/\/doi.org\/10.1371\/journal.pone.0015167.","journal-title":"PLoS One"},{"key":"735_CR145","doi-asserted-by":"publisher","unstructured":"Du Z, Zhou Y, Xie Y, Yin T, Xie Y. Abstract 14975: SIRT1 Ameliorates Cardiac Dysfunction Caused by Lamin A\/C Deficiency via Mitochondrial Bioenergetics Improvement. Circulation. 2023;148, A14975-A14975. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.14975","DOI":"10.1161\/circ.148.suppl_1.14975"},{"key":"735_CR146","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijcard.2022.06.038","volume":"363","author":"L Yang","year":"2022","unstructured":"Yang L, et al. The LMNA p.R541C mutation causes dilated cardiomyopathy in human and mice. Int J Cardiol. 2022;363:149\u201358. https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.038.","journal-title":"Int J Cardiol"},{"key":"735_CR147","doi-asserted-by":"publisher","first-page":"E438","DOI":"10.1210\/jc.2011-2587","volume":"97","author":"A Sleigh","year":"2012","unstructured":"Sleigh A, et al. Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. J Clin Endocrinol Metab. 2012;97:E438\u2013442. https:\/\/doi.org\/10.1210\/jc.2011-2587.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR148","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1582-4934.2009.00690.x","volume":"13","author":"V Verstraeten","year":"2009","unstructured":"Verstraeten V, et al. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress. J Cell Mol Med. 2009;13:959\u201371. https:\/\/doi.org\/10.1111\/j.1582-4934.2009.00690.x.","journal-title":"J Cell Mol Med"},{"key":"735_CR149","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186:243\u201378. https:\/\/doi.org\/10.1016\/j.cell.2022.11.001.","journal-title":"Cell"},{"key":"735_CR150","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jprot.2013.08.008","volume":"91","author":"J Rivera-Torres","year":"2013","unstructured":"Rivera-Torres J, et al. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture. J Proteomics. 2013;91:466\u201377. https:\/\/doi.org\/10.1016\/j.jprot.2013.08.008.","journal-title":"J Proteomics"},{"key":"735_CR151","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41419-022-05168-y","volume":"13","author":"G Catarinella","year":"2022","unstructured":"Catarinella G, et al. SerpinE1 drives a cell-autonomous pathogenic signaling in Hutchinson-Gilford Progeria syndrome. Cell Death Dis. 2022;13:737. https:\/\/doi.org\/10.1038\/s41419-022-05168-y.","journal-title":"Cell Death Dis"},{"key":"735_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020275","author":"F Monterrubio-Ledezma","year":"2023","unstructured":"Monterrubio-Ledezma F, et al. Rescue of mitochondrial function in Hutchinson-Gilford progeria syndrome by the pharmacological modulation of exportin CRM1. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12020275.","journal-title":"Cells"},{"key":"735_CR153","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/hmg\/ddr327","volume":"20","author":"SA Richards","year":"2011","unstructured":"Richards SA, Muter J, Ritchie P, Lattanzi G, Hutchison CJ. The accumulation of un-repairable DNA damage in laminopathy Progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteine. Hum Mol Genet. 2011;20:3997\u20134004. https:\/\/doi.org\/10.1093\/hmg\/ddr327.","journal-title":"Hum Mol Genet"},{"key":"735_CR154","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.18632\/aging.102941","volume":"12","author":"X Mao","year":"2020","unstructured":"Mao X, Bharti P, Thaivalappil A, Cao K. Peroxisomal abnormalities and catalase deficiency in Hutchinson-Gilford Progeria syndrome. Aging. 2020;12:5195\u2013208. https:\/\/doi.org\/10.18632\/aging.102941.","journal-title":"Aging"},{"key":"735_CR155","doi-asserted-by":"publisher","first-page":"9948","DOI":"10.1093\/nar\/gkac741","volume":"50","author":"S Maynard","year":"2022","unstructured":"Maynard S, et al. Lamin A\/C impairments cause mitochondrial dysfunction by attenuating PGC1alpha and the NAMPT-NAD\u2009+\u2009pathway. Nucleic Acids Res. 2022;50:9948\u201365. https:\/\/doi.org\/10.1093\/nar\/gkac741.","journal-title":"Nucleic Acids Res"},{"key":"735_CR156","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jprot.2013.08.008","volume":"91","author":"J Rivera-Torres","year":"2013","unstructured":"Rivera-Torres J, et al. Identification of mitochondrial dysfunction in Hutchinson\u2013Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture. J Proteomics. 2013;91:466\u201377. https:\/\/doi.org\/10.1016\/j.jprot.2013.08.008.","journal-title":"J Proteomics"},{"key":"735_CR157","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1161\/circulationaha.112.000571","volume":"127","author":"R Villa-Bellosta","year":"2013","unstructured":"Villa-Bellosta R, et al. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford Progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation. 2013;127:2442\u201351. https:\/\/doi.org\/10.1161\/circulationaha.112.000571.","journal-title":"Circulation"},{"key":"735_CR158","doi-asserted-by":"publisher","first-page":"13049","DOI":"10.1073\/pnas.192460799","volume":"99","author":"MO Bergo","year":"2002","unstructured":"Bergo MO, et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A. 2002;99:13049\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"735_CR159","unstructured":"Osorio F et al. (2011)."},{"key":"735_CR160","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/dgd.12251","volume":"58","author":"V Swahari","year":"2016","unstructured":"Swahari V, Nakamura A. Speeding up the clock: the past, present and future of Progeria. Dev Growth Differ. 2016;58:116\u201330. https:\/\/doi.org\/10.1111\/dgd.12251.","journal-title":"Dev Growth Differ"},{"key":"735_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110784","volume":"130","author":"A Zaghini","year":"2020","unstructured":"Zaghini A, et al. Long term breeding of the Lmna G609G progeric mouse: characterization of homozygous and heterozygous models. Exp Gerontol. 2020;130:110784. https:\/\/doi.org\/10.1016\/j.exger.2019.110784.","journal-title":"Exp Gerontol"},{"key":"735_CR162","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.celrep.2018.07.089","volume":"24","author":"C B\u00e1rcena","year":"2018","unstructured":"B\u00e1rcena C, et al. Methionine restriction extends lifespan in progeroid mice and alters lipid and bile acid metabolism. Cell Rep. 2018;24:2392\u2013403. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.089.","journal-title":"Cell Rep"},{"key":"735_CR163","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12852","volume":"18","author":"R Kreienkamp","year":"2019","unstructured":"Kreienkamp R, et al. Doubled lifespan and patient-like pathologies in progeria mice fed high-fat diet. Aging Cell. 2019;18:e12852. https:\/\/doi.org\/10.1111\/acel.12852.","journal-title":"Aging Cell"},{"key":"735_CR164","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European society of cardiology (ESC). Eur Heart J. 2023;44:3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"},{"key":"735_CR165","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/heartjnl-2017-312338","volume":"104","author":"G Captur","year":"2018","unstructured":"Captur G, et al. Lamin and the heart. Heart. 2018;104:468\u201379. https:\/\/doi.org\/10.1136\/heartjnl-2017-312338.","journal-title":"Heart"},{"key":"735_CR166","doi-asserted-by":"publisher","first-page":"331","DOI":"10.5603\/CJ.a2014.0037","volume":"21","author":"F Tesson","year":"2014","unstructured":"Tesson F, et al. Lamin A\/C mutations in dilated cardiomyopathy. Cardiol J. 2014;21:331\u201342. https:\/\/doi.org\/10.5603\/CJ.a2014.0037.","journal-title":"Cardiol J"},{"key":"735_CR167","unstructured":"Mitchell LB, Lamin AC, Cardiomyopathies (Cardiolaminopathies), editors. https:\/\/www.msdmanuals.com\/professional\/cardiovascular-disorders\/arrhythmogenic-cardiac-disorders\/lamin-a-c-cardiomyopathies-cardiolaminopathies (2024)."},{"key":"735_CR168","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.hrthm.2013.06.020","volume":"10","author":"F Anselme","year":"2013","unstructured":"Anselme F, et al. Implantable cardioverter-defibrillators in lamin A\/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492\u20138. https:\/\/doi.org\/10.1016\/j.hrthm.2013.06.020. https:\/\/doi.org:.","journal-title":"Heart Rhythm"},{"key":"735_CR169","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.118.039410","volume":"140","author":"K Wahbi","year":"2019","unstructured":"Wahbi K, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation. 2019;140:293\u2013302. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039410.","journal-title":"Circulation"},{"key":"735_CR170","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/eurheartj\/ehx596","volume":"39","author":"NE Hasselberg","year":"2018","unstructured":"Hasselberg NE, et al. Lamin A\/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J. 2018;39:853\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx596.","journal-title":"Eur Heart J"},{"key":"735_CR171","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.123.011548","volume":"17","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, et al. REALM-DCM: a phase 3, multinational, randomized, placebo-controlled trial of ARRY-371797 in patients with symptomatic LMNA-related dilated cardiomyopathy. Circ Heart Fail. 2024;17:e011548. https:\/\/doi.org\/10.1161\/circheartfailure.123.011548.","journal-title":"Circ Heart Fail"},{"key":"735_CR172","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1093\/hmg\/dds265","volume":"21","author":"A Muchir","year":"2012","unstructured":"Muchir A, et al. Abnormal p38\u03b1 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A\/C gene mutation. Hum Mol Genet. 2012;21:4325\u201333. https:\/\/doi.org\/10.1093\/hmg\/dds265.","journal-title":"Hum Mol Genet"},{"key":"735_CR173","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/eurheartj\/ehac305","volume":"43","author":"I Perea-Gil","year":"2022","unstructured":"Perea-Gil I, et al. Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022;43:3477\u201389. https:\/\/doi.org\/10.1093\/eurheartj\/ehac305.","journal-title":"Eur Heart J"},{"key":"735_CR174","doi-asserted-by":"publisher","unstructured":"Kay M, et al. Enhancing cardiac Serine biosynthesis mitigates the progression of dilated cardiomyopathy. Metabolism. 2025;156395. https:\/\/doi.org\/10.1016\/j.metabol.2025.156395.","DOI":"10.1016\/j.metabol.2025.156395"},{"key":"735_CR175","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41569-022-00751-4","volume":"19","author":"I Fern\u00e1ndez-Ruiz","year":"2022","unstructured":"Fern\u00e1ndez-Ruiz I. Modulating serine biosynthesis for the treatment of dilated cardiomyopathy. Nat Rev Cardiol. 2022;19:575\u2013575. https:\/\/doi.org\/10.1038\/s41569-022-00751-4.","journal-title":"Nat Rev Cardiol"},{"key":"735_CR176","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1093\/eurheartj\/ehac397","volume":"43","author":"T Eschenhagen","year":"2022","unstructured":"Eschenhagen T. Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathy. Eur Heart J. 2022;43:3490\u20132. https:\/\/doi.org\/10.1093\/eurheartj\/ehac397.","journal-title":"Eur Heart J"},{"key":"735_CR177","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1055\/s-0031-1301284","volume":"44","author":"A Luedtke","year":"2012","unstructured":"Luedtke A, et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. Horm Metab Res. 2012;44:306\u201311. https:\/\/doi.org\/10.1055\/s-0031-1301284.","journal-title":"Horm Metab Res"},{"key":"735_CR178","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cmet.2011.05.012","volume":"14","author":"W Tang","year":"2011","unstructured":"Tang W, Zeve D, Seo J, Jo AY, Graff JM. Thiazolidinediones regulate adipose lineage dynamics. Cell Metab. 2011;14:116\u201322. https:\/\/doi.org\/10.1016\/j.cmet.2011.05.012.","journal-title":"Cell Metab"},{"key":"735_CR179","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.nutr.22.010402.102808","volume":"22","author":"F Picard","year":"2002","unstructured":"Picard F, Auwerx J. PPAR\u03b3 AND GLUCOSE HOMEOSTASIS. Annu Rev Nutr. 2002;22:167\u201397. https:\/\/doi.org\/10.1146\/annurev.nutr.22.010402.102808.","journal-title":"Annu Rev Nutr"},{"key":"735_CR180","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/818945","volume":"2009","author":"A Leonardini","year":"2009","unstructured":"Leonardini A, Laviola L, Perrini S, Natalicchio A, Giorgino F. Cross-talk between PPAR\u03b3 and insulin signaling and modulation of insulin sensitivity. PPAR Res. 2009;2009:818945. https:\/\/doi.org\/10.1155\/2009\/818945.","journal-title":"PPAR Res"},{"key":"735_CR181","doi-asserted-by":"publisher","first-page":"642908","DOI":"10.3389\/fphys.2021.642908","volume":"12","author":"X Dong","year":"2021","unstructured":"Dong X, et al. Metformin increases sarcolemma integrity and ameliorates neuromuscular deficits in a murine model of Duchenne muscular dystrophy. Front Physiol. 2021;12:642908. https:\/\/doi.org\/10.3389\/fphys.2021.642908.","journal-title":"Front Physiol"},{"key":"735_CR182","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s13063-016-1503-1","volume":"17","author":"P Hafner","year":"2016","unstructured":"Hafner P, et al. Treatment with L-citrulline and Metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial. Trials. 2016;17:389. https:\/\/doi.org\/10.1186\/s13063-016-1503-1.","journal-title":"Trials"},{"key":"735_CR183","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1330797","author":"A Buczy\u0144ska","year":"2024","unstructured":"Buczy\u0144ska A, Sidorkiewicz I, Kr\u0119towski AJ, Adamska A. Examining the clinical relevance of metformin as an antioxidant intervention. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1330797.","journal-title":"Front Pharmacol"},{"key":"735_CR184","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1177\/15353702231191178","volume":"248","author":"Y Wu","year":"2023","unstructured":"Wu Y. Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity. Exp Biol Med (Maywood). 2023;248:1556\u201365. https:\/\/doi.org\/10.1177\/15353702231191178.","journal-title":"Exp Biol Med (Maywood)"},{"key":"735_CR185","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121\u201335. https:\/\/doi.org\/10.1038\/nrm.2017.95.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"735_CR186","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbadis.2018.01.018","volume":"1864","author":"S Karnewar","year":"2018","unstructured":"Karnewar S, et al. Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: relevance in age-associated vascular dysfunction. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2018;1864:1115\u201328. https:\/\/doi.org\/10.1016\/j.bbadis.2018.01.018.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"735_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63279-4","volume":"16","author":"N-L Kazakou","year":"2025","unstructured":"Kazakou N-L, et al. Metformin alters mitochondria-related metabolism and enhances human oligodendrocyte function. Nat Commun. 2025;16:8126. https:\/\/doi.org\/10.1038\/s41467-025-63279-4.","journal-title":"Nat Commun"},{"key":"735_CR188","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053533","volume":"8","author":"JM Kristensen","year":"2013","unstructured":"Kristensen JM, Larsen S, Helge JW, Dela F, Wojtaszewski JFP. Two weeks of Metformin treatment enhances mitochondrial respiration in skeletal muscle of AMPK kinase dead but not wild type mice. PLOS ONE. 2013;8:e53533. https:\/\/doi.org\/10.1371\/journal.pone.0053533.","journal-title":"PLOS ONE"},{"key":"735_CR189","doi-asserted-by":"publisher","first-page":"e1914171","DOI":"10.1001\/jamanetworkopen.2019.14171","volume":"2","author":"P Hafner","year":"2019","unstructured":"Hafner P, et al. Effect of combination l-Citrulline and Metformin treatment on motor function in patients with Duchenne muscular dystrophy: A randomized clinical trial. JAMA Netw Open. 2019;2:e1914171. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14171.","journal-title":"JAMA Netw Open"},{"key":"735_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103351","volume":"76","author":"ED Cohen","year":"2024","unstructured":"Cohen ED, et al. PPAR\u03b3 drives mitochondrial stress signaling and the loss of atrial cardiomyocytes in newborn mice exposed to hyperoxia. Redox Biol. 2024;76:103351. https:\/\/doi.org\/10.1016\/j.redox.2024.103351.","journal-title":"Redox Biol"},{"key":"735_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107705","volume":"219","author":"S Jamwal","year":"2021","unstructured":"Jamwal S, Blackburn JK, Elsworth JD. PPAR\u03b3\/PGC1\u03b1 signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Ther. 2021;219:107705. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107705.","journal-title":"Pharmacol Ther"},{"key":"735_CR192","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/toxsci\/kfj062","volume":"90","author":"MA Peraza","year":"2006","unstructured":"Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 2006;90:269\u201395.","journal-title":"Toxicol Sci"},{"key":"735_CR193","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1152\/physrev.00032.2020","volume":"101","author":"K Lim","year":"2021","unstructured":"Lim K, Haider A, Adams C, Sleigh A, Savage DB. Lipodistrophy: a paradigm for understanding the consequences of overloading adipose tissue. Physiol Rev. 2021;101:907\u201393. https:\/\/doi.org\/10.1152\/physrev.00032.2020.","journal-title":"Physiol Rev"},{"key":"735_CR194","doi-asserted-by":"publisher","unstructured":"IMAM SK, et al. 313-OR: the efficacy and safety of Glucagon-Like-Peptide-1 agonists in patients with Familial partial lipodystrophy. Diabetes. 2023;72. https:\/\/doi.org\/10.2337\/db23-313-OR.","DOI":"10.2337\/db23-313-OR"},{"key":"735_CR195","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","volume":"127","author":"CF Shaefer Jr","year":"2015","unstructured":"Shaefer CF Jr, Pamela K, Aguilar R. User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127:818\u201326. https:\/\/doi.org\/10.1080\/00325481.2015.1090295.","journal-title":"Postgrad Med"},{"key":"735_CR196","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","volume":"63","author":"Y-S Lee","year":"2014","unstructured":"Lee Y-S, Jun H-S. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metab Clin Exp. 2014;63:9\u201319. https:\/\/doi.org\/10.1016\/j.metabol.2013.09.010.","journal-title":"Metab Clin Exp"},{"key":"735_CR197","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1161\/circulationaha.116.022965","volume":"134","author":"FS Collins","year":"2016","unstructured":"Collins FS. Seeking a cure for one of the rarest diseases: Progeria. Circulation. 2016;134:126\u20139. https:\/\/doi.org\/10.1161\/circulationaha.116.022965.","journal-title":"Circulation"},{"key":"735_CR198","doi-asserted-by":"publisher","first-page":"A34","DOI":"10.1210\/jendso\/bvac150.071","volume":"6","author":"MF De Freitas","year":"2022","unstructured":"De Freitas MF, et al. RF24 | PSUN126 A Very-Low calorie diet can reduce insulin resistance and cause remission of diabetes mellitus and hypertriglyceridemia in a patient with Familial partial lipodystrophy type 2. J Endocr Soc. 2022;6:A34.","journal-title":"J Endocr Soc"},{"key":"735_CR199","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4274\/jcrpe.galenos.2019.2019.0124","volume":"12","author":"S \u00d6zen","year":"2020","unstructured":"\u00d6zen S, Ak\u0131nc\u0131 B, Oral EA. Current diagnosis, treatment and clinical challenges in the management of lipodystrophy syndromes in children and young people. J Clin Res Pediatr Endocrinol. 2020;12:17\u201328. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2019.2019.0124.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"735_CR200","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1210\/clinem\/dgac079","volume":"107","author":"LT Fourman","year":"2022","unstructured":"Fourman LT, Grinspoon SK. Approach to the patient with lipodystrophy. J Clin Endocrinol Metab. 2022;107:1714\u201326. https:\/\/doi.org\/10.1210\/clinem\/dgac079.","journal-title":"J Clin Endocrinol Metab"},{"key":"735_CR201","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000522620","volume":"95","author":"F Mainieri","year":"2022","unstructured":"Mainieri F, Chiarelli F. Lipodystrophies in children. Horm Res Paediatr. 2022;95:305\u201320. https:\/\/doi.org\/10.1159\/000522620.","journal-title":"Horm Res Paediatr"},{"key":"735_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1343548","volume":"11","author":"F Valoriani","year":"2024","unstructured":"Valoriani F, Pinelli G, Gabriele S, Menozzi R. Effect of nutritional therapy in Emery-Dreifuss muscular dystrophy: a case report. Front Nutr. 2024;11:1343548. https:\/\/doi.org\/10.3389\/fnut.2024.1343548.","journal-title":"Front Nutr"},{"key":"735_CR203","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007573","volume":"12","author":"LC Joseph","year":"2019","unstructured":"Joseph LC, et al. Dietary saturated fat promotes arrhythmia by activating NOX2 (NADPH oxidase 2). Circulation: Arrhythmia and Electrophysiology. 2019;12:e007573. https:\/\/doi.org\/10.1161\/CIRCEP.119.007573.","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"key":"735_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9101012","author":"BH Gowen","year":"2020","unstructured":"Gowen BH, Reyes MV, Joseph LC, Morrow JP. Mechanisms of chronic metabolic stress in arrhythmias. Antioxidants. 2020. https:\/\/doi.org\/10.3390\/antiox9101012.","journal-title":"Antioxidants"},{"key":"735_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091293","author":"Y Higashi","year":"2023","unstructured":"Higashi Y. Endothelial function in dyslipidemia: roles of LDL-cholesterol, HDL-cholesterol and triglycerides. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12091293.","journal-title":"Cells"},{"key":"735_CR206","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1139\/apnm-2015-0006","volume":"40","author":"CA Dow","year":"2015","unstructured":"Dow CA, Stauffer BL, Greiner JJ, DeSouza CA. Influence of habitual high dietary fat intake on endothelium-dependent vasodilation. Appl Physiol Nutr Metab. 2015;40:711\u20135. https:\/\/doi.org\/10.1139\/apnm-2015-0006.","journal-title":"Appl Physiol Nutr Metab"},{"key":"735_CR207","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/19491034.2019.1589359","volume":"10","author":"MR Hamczyk","year":"2019","unstructured":"Hamczyk MR, Andr\u00e9s V. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford Progeria syndrome. Nucleus. 2019;10:48\u201354. https:\/\/doi.org\/10.1080\/19491034.2019.1589359.","journal-title":"Nucleus"},{"key":"735_CR208","doi-asserted-by":"publisher","first-page":"439","DOI":"10.5551\/jat.RV17061","volume":"29","author":"H Kato","year":"2022","unstructured":"Kato H, Maezawa Y. Atherosclerosis and cardiovascular diseases in progeroid syndromes. J Atheroscler Thromb. 2022;29:439\u201347. https:\/\/doi.org\/10.5551\/jat.RV17061.","journal-title":"J Atheroscler Thromb"},{"key":"735_CR209","doi-asserted-by":"publisher","first-page":"12826","DOI":"10.1038\/s41598-024-63711-7","volume":"14","author":"S-W Pan","year":"2024","unstructured":"Pan S-W, et al. Creatine and l-carnitine attenuate muscular laminopathy in the LMNA mutation Transgenic zebrafish. Sci Rep. 2024;14:12826. https:\/\/doi.org\/10.1038\/s41598-024-63711-7.","journal-title":"Sci Rep"},{"key":"735_CR210","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/antiox11020351","volume":"11","author":"J-C Chiang","year":"2022","unstructured":"Chiang J-C, Chen W-M, Newman C, Chen BPC, Lee H. Lysophosphatidic Acid Receptor 3 Promotes Mitochondrial Homeostasis against Oxidative Stress: Potential Therapeutic Approaches for Hutchinson-Gilford Progeria Syndrome. Antioxidants. 2022;11:351.","journal-title":"Antioxidants"},{"key":"735_CR211","doi-asserted-by":"publisher","first-page":"e13064","DOI":"10.1111\/acel.13064","volume":"19","author":"WM Chen","year":"2020","unstructured":"Chen WM, et al. Lysophosphatidic acid receptor LPA(3) prevents oxidative stress and cellular senescence in Hutchinson-Gilford Progeria syndrome. Aging Cell. 2020;19:e13064. https:\/\/doi.org\/10.1111\/acel.13064.","journal-title":"Aging Cell"},{"key":"735_CR212","doi-asserted-by":"publisher","first-page":"872","DOI":"10.4161\/cc.24061","volume":"12","author":"S Ghosh","year":"2013","unstructured":"Ghosh S, Liu B, Zhou Z. Resveratrol activates SIRT1 in a lamin A-dependent manner. Cell Cycle. 2013;12:872\u20136. https:\/\/doi.org\/10.4161\/cc.24061.","journal-title":"Cell Cycle"},{"key":"735_CR213","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1096\/fj.14-269217","volume":"29","author":"C Strandgren","year":"2015","unstructured":"Strandgren C, et al. Transgene Silencing of the Hutchinson-Gilford Progeria syndrome mutation results in a reversible bone phenotype, whereas Resveratrol treatment does not show overall beneficial effects. FASEB J. 2015;29:3193\u2013205. https:\/\/doi.org\/10.1096\/fj.14-269217. https:\/\/doi.org:.","journal-title":"FASEB J"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00735-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00735-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00735-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:01:29Z","timestamp":1770022889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00735-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":213,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00735-8","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heymans, S.R, B. receives personal fees for independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, Merck and CSL Behring, and receives research support from AstraZeneca and CSL Behring. Torfs, T., Veltrop, R.J.A., Lezzoche, G., Verdonschot, J.A.J., and Nabben, M. declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}